Table 2.

Reported NAb Formation Frequency in Therapeutic Indications, by Formulation^*

Formulation	NAb Formation Frequency (%)	No. Publications
ABO	0–13.3	621,23,25–28
ONA†	0.9–5.6	321,26,28
ONA (new)	0.3–4.0	323,25,27
ONA (old)	7.2	127
INCO‡	0–1.1	621,23,25–28
Not specified	1.9–2.5	221,27

*Estimates in these studies may be associated with either overall use or exclusive use of the BoNT-A formulations studied.

†This publication did not distinguish between the old and new formulations of ONA.

‡Most patients had previously received ABO and/or ONA.